{"id":3324,"date":"2018-09-03T10:53:59","date_gmt":"2018-09-03T14:53:59","guid":{"rendered":"http:\/\/www.drugpatentwatch.com\/blog\/?p=3324"},"modified":"2026-09-27T20:46:48","modified_gmt":"2026-09-28T00:46:48","slug":"how-long-do-drug-patents-last","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/how-long-do-drug-patents-last\/","title":{"rendered":"How Long Do Drug Patents Last? 20 Years on Paper, About 14 in Practice"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

A US patent lasts 20 years from filing [1]. A study of 264 small-molecule drugs that faced new generic competition from 2012 through 2018 found a median market exclusivity of 14.4 years [2]. The gap comes from clinical trials and FDA review, which use up patent term before the first sale [5].<\/p>\n\n\n\n

Humira ran well past that median. AbbVie launched it in January 2003 [3]. US loss of exclusivity came on January 31, 2023 [4]. That is 20 years of US market exclusivity (calculation). The US compound patent expired in December 2016 [3], so biosimilar entry came about six years and one month after the key patent expired (calculation).<\/p>\n\n\n\n

This guide covers each clock that sets the length of drug protection: patent term, patent term adjustment, patent term extension, FDA exclusivities, biologic rules, litigation events, and Medicare negotiation. It relies on FDA, court, CMS, Federal Register, and SEC records where they exist. Calculations are labeled as calculations. Information is current as of September 27, 2026.<\/p>\n\n\n\n

How Long Does a Drug Patent Last? The Short Answer<\/strong><\/h2>\n\n\n\n

A drug patent lasts 20 years from the filing date of the US application, unless the term is adjusted or extended [1]. Four mechanisms change the practical length:<\/p>\n\n\n\n

    \n
  • Patent term adjustment (PTA) adds one day for each day of qualifying USPTO delay, minus applicant delay [6].<\/li>\n\n\n\n
  • Patent term extension (PTE) restores up to 5 years for FDA review time. Post-approval patent life with the extension cannot exceed 14 years [5].<\/li>\n\n\n\n
  • Pediatric exclusivity adds 6 months to listed patents and exclusivities. It does not extend the patent itself [7].<\/li>\n\n\n\n
  • Regulatory exclusivities, such as 5-year new chemical entity (NCE) exclusivity, run on their own clocks and can start or end independently of any patent [1].<\/li>\n<\/ul>\n\n\n\n

    The 20-year rule<\/strong><\/h3>\n\n\n\n

    Patents granted after the Uruguay Round Agreements Act took effect on June 8, 1995 last 20 years from the first filing date. Earlier patents generally lasted 17 years from issue [5]. The clock starts at filing, not at approval or launch.<\/p>\n\n\n\n

    Why the effective term is shorter than 20 years<\/strong><\/h3>\n\n\n\n

    FDA states that the effective patent term is frequently shorter than 20 years because inventors obtain patents before products reach the market [5]. New human drugs generally need animal and human testing before approval [5]. The difference between the 20-year term and the 14.4-year median market exclusivity is 5.6 years (calculation). That figure is not a measured patent life. Observed market exclusivity also reflects extensions, secondary patents, and settlements (interpretation).<\/p>\n\n\n\n

    Patent Term, Exclusivity, and Market Exclusivity: Five Different Clocks<\/strong><\/h2>\n\n\n\n

    FDA separates patents from exclusivity. Patents are property rights granted by the USPTO. Exclusivity is a delay or bar on approval of competing drugs that attaches when FDA approves a drug or certain supplements [1]. The two may or may not run at the same time [1].<\/p>\n\n\n\n

    Clock<\/th>What starts it<\/th>Length<\/th>What it does<\/th>Source<\/th><\/tr><\/thead>
    Patent term<\/td>Earliest US filing date<\/td>20 years<\/td>Right to exclude, granted by USPTO<\/td>[1]<\/td><\/tr>
    Patent term adjustment<\/td>USPTO examination delay<\/td>1 day per qualifying day, net of applicant delay<\/td>Adds days to the term<\/td>[6]<\/td><\/tr>
    Patent term extension<\/td>FDA approval, application within 60 days<\/td>Up to 5 years; 14-year post-approval ceiling<\/td>Extends one eligible patent<\/td>[5]<\/td><\/tr>
    Regulatory exclusivity<\/td>FDA approval<\/td>NCE 5 years; NCI 3 years; orphan 7 years; pediatric +6 months<\/td>Blocks submission or approval of competing applications<\/td>[1][7]<\/td><\/tr>
    Market exclusivity<\/td>Launch to first generic or biosimilar<\/td>Median 14.4 years for small molecules (2012 to 2018 entrants)<\/td>Observed outcome, not a legal right<\/td>[2]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Terms used in this guide<\/strong><\/h3>\n\n\n\n

    These are established industry terms. This guide does not introduce new classifications.<\/p>\n\n\n\n

      \n
    • Orange Book: FDA’s “Approved Drug Products with Therapeutic Equivalence Evaluations.” It lists patent and exclusivity information for small-molecule drugs [1].<\/li>\n\n\n\n
    • Purple Book: FDA’s list of licensed biological products. Since the Biological Product Patent Transparency Act of 2020, brand biologic makers report patents identified in the patent dance for Purple Book listing [22].<\/li>\n\n\n\n
    • Paragraph IV certification: a generic applicant’s assertion that a listed patent is invalid, unenforceable, or will not be infringed [7].<\/li>\n\n\n\n
    • Section viii statement: a statement that lets a generic seek approval while carving a patented method of use out of its label [29].<\/li>\n\n\n\n
    • ANDA: abbreviated new drug application, the generic drug pathway [7].<\/li>\n\n\n\n
    • Loss of exclusivity (LOE): the point when the last patent or exclusivity barrier to generic or biosimilar sales falls.<\/li>\n<\/ul>\n\n\n\n

      Patent Term Adjustment: Days Added for USPTO Delay<\/strong><\/h2>\n\n\n\n

      A, B, and C delay<\/strong><\/h3>\n\n\n\n

      PTA under 35 U.S.C. 154(b) compensates for USPTO delay. The calculation is USPTO delay minus applicant delay, and PTA cannot be negative [6]. A delay accrues when USPTO misses the “14-4” deadlines: a first action within 14 months of filing, then responses within 4 months [6]. B delay accrues when USPTO does not issue the patent within 3 years of filing. It excludes time in continued examination requests, appeals, and interferences [6]. C delay covers interferences, secrecy orders, and certain appeals [6].<\/p>\n\n\n\n

      How PTA differs from PTE<\/strong><\/h3>\n\n\n\n

      PTA answers USPTO examination delay [6]. PTE answers FDA review delay [5]. They use different agencies and different clocks.<\/p>\n\n\n\n

      Patent Term Extension: The Formula, Two Caps, and Six Conditions<\/strong><\/h2>\n\n\n\n

      The PTE formula<\/strong><\/h3>\n\n\n\n

      The eligible extension equals the approval phase plus one-half of the testing phase, after removing any period in which the applicant lacked due diligence [5]. Only review time after the patent issued counts [5]. For a human drug, the testing phase runs from the effective date of the investigational exemption (IND) to submission of the marketing application. The approval phase runs from submission to approval [5].<\/p>\n\n\n\n

      The 5-year cap and the 14-year cap<\/strong><\/h3>\n\n\n\n

      PTE cannot exceed 5 years. Total patent life after approval, including the extension, cannot exceed 14 years [5]. If the patent already has 14 or more years left after approval, the product is not eligible for extension [5]. FDA gives one example: a product eligible for the maximum 5 years, with 10 years of original term left after review, receives 4 years [5].<\/p>\n\n\n\n

      Worked example of the 14-year cap<\/strong><\/h4>\n\n\n\n

      Calculation: let R be the remaining original term at approval and F the formula value, both in years. The extension is the larger of zero and the smaller of F, 5, and (14 minus R). The rows below are illustrative, not real drugs.<\/p>\n\n\n\n

      Remaining term at approval (R)<\/th>Formula value (F)<\/th>Extension granted<\/th>Patent life after approval<\/th><\/tr><\/thead>
      8.0 years<\/td>3.0 years<\/td>3.0 years<\/td>11.0 years<\/td><\/tr>
      10.0 years<\/td>5.0 years<\/td>4.0 years (matches FDA example)<\/td>14.0 years<\/td><\/tr>
      13.5 years<\/td>2.0 years<\/td>0.5 years<\/td>14.0 years<\/td><\/tr>
      14.5 years<\/td>3.0 years<\/td>None (ineligible)<\/td>14.5 years<\/td><\/tr>
      2.0 years<\/td>8.0 years<\/td>5.0 years (5-year cap)<\/td>7.0 years<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

      The six eligibility conditions<\/strong><\/h3>\n\n\n\n

      FDA lists six conditions for extending a patent that claims a human drug product, a method of using it, or a method of manufacturing it [5]:<\/p>\n\n\n\n

        \n
      1. The patent has not expired.<\/li>\n\n\n\n
      2. The patent has not previously been extended.<\/li>\n\n\n\n
      3. The owner or its agent submits an application with details about the patent and the FDA approval activities.<\/li>\n\n\n\n
      4. The product was subject to a regulatory review period before commercial marketing.<\/li>\n\n\n\n
      5. The approval is the first permitted commercial marketing or use of the product.<\/li>\n\n\n\n
      6. The application reaches USPTO within 60 days of FDA approval.<\/li>\n<\/ol>\n\n\n\n

        Active ingredient, not active moiety<\/strong><\/h4>\n\n\n\n

        For PTE, FDA defines the product by its active ingredient, not its active moiety. A new ester or salt of a previously approved acid is eligible. A new acid of a previously approved salt or ester is not [5]. NCE exclusivity uses the opposite test. It turns on the active moiety, and a salt of an approved drug is generally not a new active moiety [7].<\/p>\n\n\n\n

        Which patents qualify<\/strong><\/h4>\n\n\n\n

        For combination products, at least one active ingredient must be new to FDA. Only the patent covering the new component or the combination may be extended [5].<\/p>\n\n\n\n

        Who decides what: FDA and USPTO<\/strong><\/h3>\n\n\n\n

        FDA verifies the dates, determines the regulatory review period, and publishes it in the Federal Register. USPTO determines the length of the extension [5]. Any person can file a due diligence petition within 180 days of the Federal Register notice. FDA’s FAQ, current as of August 15, 2025, states that no due diligence petition has been submitted [5].<\/p>\n\n\n\n

        What FDA’s Published Review Periods Show: Seven Recent Determinations<\/strong><\/h2>\n\n\n\n

        Federal Register notices give the exact testing and approval phases for each product. The table lists seven notices, including three drugs and four biologics. All formula values are calculations. The methodology section explains the limits.<\/p>\n\n\n\n

        Data table: review periods and formula ceilings<\/strong><\/h3>\n\n\n\n
        Product<\/th>Notice date<\/th>Testing phase (days)<\/th>Approval phase (days)<\/th>Total (days)<\/th>Formula ceiling (days)<\/th>Formula ceiling (years)<\/th>Above 5-year cap?<\/th>Source<\/th><\/tr><\/thead>
        ELIQUIS<\/td>Dec 10, 2015<\/td>3,227<\/td>458<\/td>3,685<\/td>2,071.5<\/td>5.67<\/td>Yes<\/td>[8]<\/td><\/tr>
        ALIQOPA<\/td>Feb 14, 2023<\/td>2,821<\/td>183*<\/td>3,004<\/td>1,593.5<\/td>4.36<\/td>No<\/td>[9]<\/td><\/tr>
        EXBLIFEP<\/td>Jan 27, 2026<\/td>2,128<\/td>246<\/td>2,374<\/td>1,310.0<\/td>3.59<\/td>No<\/td>[10]<\/td><\/tr>
        AMTAGVI<\/td>Feb 13, 2026<\/td>2,969<\/td>337<\/td>3,306<\/td>1,821.5<\/td>4.99<\/td>No<\/td>[13]<\/td><\/tr>
        VYLOY<\/td>Apr 3, 2026<\/td>1,945<\/td>526<\/td>2,471<\/td>1,498.5<\/td>4.10<\/td>No<\/td>[11]<\/td><\/tr>
        ENFLONSIA<\/td>Apr 3, 2026<\/td>2,713<\/td>243<\/td>2,956<\/td>1,599.5<\/td>4.38<\/td>No<\/td>[12]<\/td><\/tr>
        ENCELTO<\/td>Apr 3, 2026<\/td>7,581<\/td>322<\/td>7,903<\/td>4,112.5<\/td>11.26<\/td>Yes<\/td>[14]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

        *Approval phase derived by subtracting the testing phase from the total in the notice. ELIQUIS, ALIQOPA, and EXBLIFEP are drug products. AMTAGVI, VYLOY, ENFLONSIA, and ENCELTO are biological products, so PTE applies to BLA-based products as well [5][11][12][13][14].<\/p>\n\n\n\n

        Findings<\/strong><\/h3>\n\n\n\n
          \n
        • The formula ceiling ranged from 1,310 days (3.59 years) for EXBLIFEP to 4,112.5 days (11.26 years) for ENCELTO. The median was 1,599.5 days (4.38 years) (calculation).<\/li>\n\n\n\n
        • The testing phase made up 78.7% to 95.9% of the total review period in each case (calculation).<\/li>\n\n\n\n
        • Even at half weight, the testing phase supplied 64.9% (VYLOY) to 92.2% (ENCELTO) of each formula ceiling (calculation).<\/li>\n\n\n\n
        • For ELIQUIS, the applicant sought 1,424 days [8]. The formula ceiling was 2,071.5 days (calculation). The notice says USPTO applies statutory limitations and does not itemize which one applied [8].<\/li>\n\n\n\n
        • For ALIQOPA, the applicant sought 1,594 days for one patent and 692 days for another [9]. The same review period yields different requests because only review time after a patent issued counts [5].<\/li>\n<\/ul>\n\n\n\n

          The testing phase drives the credit<\/strong><\/h4>\n\n\n\n

          PTE works mainly as a credit for clinical development time. The approval phase counts in full but is short. It supplied 7.8% to 35.1% of the formula ceiling in these seven records (calculation).<\/p>\n\n\n\n

          Two of seven exceed the 5-year cap<\/strong><\/h4>\n\n\n\n

          ELIQUIS and ENCELTO exceed the 5-year cap on the formula alone. The 5-year cap equals about 1,826 days (5 x 365.25). AMTAGVI falls 4.75 days under it (calculation).<\/p>\n\n\n\n

          Regulatory Exclusivity: Clocks That Run Without Patents<\/strong><\/h2>\n\n\n\n
          Exclusivity<\/th>Length<\/th>Effect<\/th>Source<\/th><\/tr><\/thead>
          New chemical entity (NCE)<\/td>5 years<\/td>No ANDA or 505(b)(2) submission for the same active moiety, except a Paragraph IV filing at year 4<\/td>[1][7]<\/td><\/tr>
          New clinical investigation (NCI)<\/td>3 years<\/td>ANDAs can be received but not approved until it expires, unless the protected information can be carved out of the label<\/td>[7]<\/td><\/tr>
          Orphan drug (ODE)<\/td>7 years<\/td>Listed in the Orange Book once granted<\/td>[1][7]<\/td><\/tr>
          Pediatric<\/td>6 months added<\/td>Attaches to listed patents and exclusivities<\/td>[1][7]<\/td><\/tr>
          GAIN (qualified infectious disease products)<\/td>5 years added<\/td>Added to certain exclusivities<\/td>[1][7]<\/td><\/tr>
          Patent challenge (PC)<\/td>180 days<\/td>Reward for the first Paragraph IV ANDA applicant<\/td>[1][7]<\/td><\/tr>
          Competitive generic therapy (CGT)<\/td>180 days<\/td>ANDA-only incentive where generic competition is inadequate<\/td>[1][7]<\/td><\/tr>
          Biologic reference product<\/td>12 years<\/td>FDA cannot approve a biosimilar until 12 years after first approval of the reference product<\/td>[15]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

          NCE exclusivity and the NCE-1 date<\/strong><\/h3>\n\n\n\n

          During the 5 years, no applicant can submit an ANDA or 505(b)(2) application for the same active moiety. If patents are listed in the Orange Book, an applicant can submit with a Paragraph IV certification at the “NCE-1” date, which falls in year 4 [7]. If the brand sues within the 1-year window that starts 4 years after approval, the 30-month stay is extended so that 7.5 years pass from the NDA approval date [7].<\/p>\n\n\n\n

          FDA’s example: Farxiga was approved on January 8, 2014, and its NCE exclusivity expired on January 8, 2019 [7]. Calculation: the NCE-1 date was January 8, 2018, and the extended stay would run to July 8, 2021 if the brand sued inside the window.<\/p>\n\n\n\n

          Pediatric exclusivity attaches to patents<\/strong><\/h3>\n\n\n\n

          FDA adds 6 months to the end of listed patents and exclusivities. It applies to all existing patents and exclusivities on all drug products the sponsor holds for that active moiety at the time of grant [7]. It is the only exclusivity that also attaches to listed patents. It is not an extension of the patent [7].<\/p>\n\n\n\n

          How pediatric exclusivity appears in the Orange Book<\/strong><\/h4>\n\n\n\n

          The Orange Book shows the patent twice: once with the original expiration date and once with the date that includes the 6 months [1].<\/p>\n\n\n\n

          Which exclusivities can be carved out<\/strong><\/h4>\n\n\n\n

          NCI exclusivity can be avoided if the protected information can be carved out of the label. The 6-month pediatric period cannot be carved out [7].<\/p>\n\n\n\n

          The 180-day patent challenge exclusivity<\/strong><\/h3>\n\n\n\n

          The first applicant to submit a substantially complete ANDA with a Paragraph IV challenge earns 180 days. It blocks approval of later ANDAs that also contain a Paragraph IV certification. It does not block NDA marketing, including authorized generics, and applicants who file a section viii statement on the same patent are never blocked [7].<\/p>\n\n\n\n

          How Long Do Brand Drugs Actually Stay Protected? The Market Exclusivity Evidence<\/strong><\/h2>\n\n\n\n
          \n

          Rome, Lee, and Kesselheim reported that biologics had longer exclusivity than small molecules, at “median 21.5 vs. 14.4 years” [2].<\/p>\n<\/blockquote>\n\n\n\n

          Study<\/th>Cohort<\/th>Result<\/th>Source<\/th><\/tr><\/thead>
          Grabowski and Kyle (2007)<\/td>New drugs with first generic entry in 2005 and sales above $100 million<\/td>Average market exclusivity of 11.5 years<\/td>[16]<\/td><\/tr>
          Grabowski et al. (2011)<\/td>First generic entry in 2007 to 2008<\/td>11.8 years. For 2008 entrants, 92% faced a Paragraph IV challenge, on average 7.7 years after launch<\/td>[16]<\/td><\/tr>
          Kesselheim, Sinha, and Avorn (2017)<\/td>Brand-name drugs generally<\/td>Most have a 12 to 16 year window free of generic competition<\/td>[18]<\/td><\/tr>
          Grabowski et al. (2021)<\/td>New molecular entities with sales above $250 million<\/td>Averaged 13.0 years, described as relatively constant for nearly a decade<\/td>[17]<\/td><\/tr>
          Rome, Lee, and Kesselheim (2021)<\/td>264 small molecules and 4 biologics with new competition, 2012 to 2018<\/td>Median 14.4 years (small molecules); 21.5 years (biologics)<\/td>[2]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

          Definitions differ. The Grabowski studies measure launch to first generic entry, and Rome et al. use claims data. Read the rows as a range, not a trend line.<\/p>\n\n\n\n

          Small molecules: 12 to 14 years<\/strong><\/h3>\n\n\n\n

          Across these studies, small-molecule market exclusivity clusters between about 11.5 and 14.4 years. That is 5.6 to 8.5 years below the 20-year patent term (calculation).<\/p>\n\n\n\n

          Revenue and exclusivity length<\/strong><\/h4>\n\n\n\n

          Rome et al. found longer exclusivity for drugs with annual revenue under $75 million (16.6 years) than for drugs with revenue of $500 million or more [2]. Larger markets attract earlier patent challenges (interpretation).<\/p>\n\n\n\n

          Biologics: few observations, longer periods<\/strong><\/h3>\n\n\n\n

          The biologic median of 21.5 years rests on only four drugs [2]. The authors concluded that expected US market exclusivity periods are similar for biologics and small molecules, and that biosimilar competition would likely increase as the market matures [2].<\/p>\n\n\n\n

          Case Study: Humira’s 20 Years of US Exclusivity<\/strong><\/h2>\n\n\n\n

          Timeline<\/strong><\/h3>\n\n\n\n
          Date<\/th>Event<\/th>Source<\/th><\/tr><\/thead>
          January 2003<\/td>Humira introduced to the market<\/td>[3]<\/td><\/tr>
          May 2016<\/td>USPTO’s Patent Trial and Appeal Board begins instituting five inter partes reviews (Coherus and Boehringer Ingelheim) against three AbbVie methods-of-treatment patents<\/td>[3]<\/td><\/tr>
          December 2016<\/td>US compound patent for adalimumab expected to expire<\/td>[3]<\/td><\/tr>
          January 31, 2023<\/td>Loss of US exclusivity<\/td>[4]<\/td><\/tr>
          2023<\/td>US Humira sales fall 35%, driven by direct biosimilar competition<\/td>[4]<\/td><\/tr>
          Through 2037<\/td>Last patent in the portfolio expires<\/td>[19]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

          What the numbers imply<\/strong><\/h3>\n\n\n\n

          Knox and Curfman counted about 247 patent applications for Humira, of which 132 were granted. About 90% of the filings came after the drug reached the market, and almost half came in 2014 or later [19]. The grant rate was 53.4% (calculation).<\/p>\n\n\n\n

          Virtually all biosimilar developers settled with AbbVie before entry. The settlements allowed US entry in early 2023, before the last patent expired, in exchange for royalties [19]. Settlement dates, not patent expiry dates, set the entry date. Calculation: 20 years of market exclusivity, entry about 6 years and 1 month after the compound patent expired, and roughly 14 years before the last patent expires in 2037.<\/p>\n\n\n\n

          Biologics: 12-Year Exclusivity and the Patent Dance<\/strong><\/h2>\n\n\n\n

          Reference product exclusivity<\/strong><\/h3>\n\n\n\n

          The Biologics Price Competition and Innovation Act (BPCIA) bars FDA from approving a biosimilar until 12 years after first approval of the reference product [15]. DrugPatentWatch’s analysis puts pembrolizumab (Keytruda), approved in September 2014, at the September 2026 date and projects first biosimilar approvals around 2027 to 2028, with launch timing depending on patent-dance litigation or settlement [20]. The 12-year date is arithmetic. The launch date is a forecast.<\/p>\n\n\n\n

          The patent dance timeline<\/strong><\/h3>\n\n\n\n
            \n
          1. Within 20 days after FDA accepts the biosimilar application, the applicant gives the reference product sponsor its application and manufacturing information [21].<\/li>\n\n\n\n
          2. Within 60 days, the sponsor lists patents it could reasonably assert [21].<\/li>\n\n\n\n
          3. Within 60 days of that list, the applicant responds with its infringement and validity positions [21].<\/li>\n\n\n\n
          4. Within another 60 days, the sponsor responds with its own positions [21].<\/li>\n\n\n\n
          5. After negotiation to narrow the patents, the sponsor may bring an infringement action [21].<\/li>\n<\/ol>\n\n\n\n

            The full process runs roughly six to eight months. No patent information reaches FDA until a dance takes place, and the patents identified are then reported for Purple Book listing [22].<\/p>\n\n\n\n

            Notice of commercial marketing<\/strong><\/h4>\n\n\n\n

            The applicant must give notice at least 180 days before first commercial marketing. That notice lets the sponsor seek a preliminary injunction on patents left out of the first infringement action [21].<\/p>\n\n\n\n

            Interchangeability status<\/strong><\/h3>\n\n\n\n

            Historically, FDA recommended dedicated switching studies to support an interchangeability designation [23]. FDA’s biosimilar guidance page, dated March 9, 2026, still lists the interchangeability update as a draft [24]. Jones Day reported in December 2025 that FDA planned to finalize the related guidance in early 2026 [23]. Check the FDA page for current status.<\/p>\n\n\n\n

            First interchangeable exclusivity<\/strong><\/h4>\n\n\n\n

            The first interchangeable exclusivity bars FDA from approving another interchangeable for the earlier of one year after first commercial marketing or a defined period of 18 to 42 months, depending on patent litigation status [23].<\/p>\n\n\n\n

            Paragraph IV, the 30-Month Stay, and Skinny Labels<\/strong><\/h2>\n\n\n\n

            The 30-month stay<\/strong><\/h3>\n\n\n\n

            When a brand lists a patent in the Orange Book and sues a generic applicant, the listing may trigger a statutory stay that generally blocks the generic for 30 months [25]. Patent listings therefore control generic timing as well as patent term.<\/p>\n\n\n\n

            Skinny-label case timeline<\/strong><\/h3>\n\n\n\n
            Date<\/th>Event<\/th>Source<\/th><\/tr><\/thead>
            October 2, 2020<\/td>Federal Circuit (2 to 1) reinstates a jury verdict that Teva induced infringement of GSK’s Coreg method patent despite a skinny label<\/td>[26]<\/td><\/tr>
            February 9, 2021<\/td>Federal Circuit grants rehearing and vacates its October 2020 opinion<\/td>[26]<\/td><\/tr>
            August 5, 2021<\/td>New Federal Circuit opinion again finds Teva liable<\/td>[26]<\/td><\/tr>
            June 2024<\/td>Federal Circuit reverses dismissal of Amarin’s inducement claim against Hikma<\/td>[27]<\/td><\/tr>
            January 16, 2026<\/td>Supreme Court grants certiorari in Hikma v. Amarin, No. 24-889<\/td>[28]<\/td><\/tr>
            June 4, 2026<\/td>Supreme Court reverses, 9 to 0, in an opinion by Justice Jackson<\/td>[29][30]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

            What the Supreme Court held<\/strong><\/h3>\n\n\n\n

            The Court held that Amarin did not plausibly allege that Hikma actively induced infringement of the patented cardiovascular use. Hikma’s skinny label, website statements, and press releases were not enough [29][30]. The decision rejects what the Court called a “trend” in Federal Circuit cases such as GSK v. Teva [30]. Ropes and Gray summarizes the holding this way: routine labeling and marketing alone do not state an inducement claim [27].<\/p>\n\n\n\n

            What the decision did not decide<\/strong><\/h4>\n\n\n\n

            The Court decided a pleading question. It did not eliminate inducement claims against skinny-label generics. It noted that active inducement need not be express and that implicit encouragement can suffice [31].<\/p>\n\n\n\n

            Effect on method-of-use patents<\/strong><\/h4>\n\n\n\n

            Interpretation: a method-of-use patent on a carved-out indication now blocks a skinny-label launch less reliably, unless the brand can plead specific acts of active encouragement. Brands that relied on such patents to extend effective exclusivity should model earlier generic entry.<\/p>\n\n\n\n

            Orange Book Listings Under Antitrust Pressure<\/strong><\/h2>\n\n\n\n

            Timeline of FTC and court actions<\/strong><\/h3>\n\n\n\n
            Date<\/th>Event<\/th>Source<\/th><\/tr><\/thead>
            September 2023<\/td>FTC issues a policy statement on improper Orange Book listings<\/td>[25]<\/td><\/tr>
            November 2023 and April 2024<\/td>FTC warning letters and notices to FDA challenging listings (the first round covered more than 100 patents)<\/td>[25][32]<\/td><\/tr>
            December 2024<\/td>Federal Circuit affirms delisting of Teva inhaler patents in Teva v. Amneal<\/td>[25][33]<\/td><\/tr>
            May 21, 2025<\/td>FTC renews challenge to more than 200 listings across 17 brand-name products<\/td>[32]<\/td><\/tr>
            October 2025<\/td>Teva agrees to a $35 million settlement in the QVAR end-payor litigation, per DrugPatentWatch tracking<\/td>[34]<\/td><\/tr>
            December 10, 2025<\/td>Teva asks FDA to remove more than 200 listings, covering more than 30 asthma, diabetes, and COPD drugs and epinephrine autoinjectors<\/td>[35]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

            What can be listed<\/strong><\/h3>\n\n\n\n

            The Federal Circuit reasoned that a patent does not properly claim a drug unless it at least claims the active ingredient. A device that merely contains the active ingredient does not qualify [33]. FDA calls its own patent-listing role ministerial [1]. NDA holders must submit patent information within 30 days of approval, and must submit a corrected expiration date within 30 days after a term extension is granted [1].<\/p>\n\n\n\n

            Why delisting matters for duration<\/strong><\/h4>\n\n\n\n

            A delisted patent can no longer support a 30-month stay [25]. As of mid-2026, DrugPatentWatch reports that the FTC has not brought a standalone Section 5 case over Orange Book listings and has relied on warning letters, FDA disputes, and amicus briefs [34].<\/p>\n\n\n\n

            The Inflation Reduction Act Adds a Statutory Clock<\/strong><\/h2>\n\n\n\n

            Eligibility clocks<\/strong><\/h3>\n\n\n\n

            A single-source drug must be at least 7 years past approval (small molecules) or 11 years past licensure (biologics) on the date CMS publishes the selected drug list. For the 2028 cycle, that means small molecules approved on or before February 1, 2019 and biologics licensed on or before February 1, 2015 [36]. CMS uses the earliest approval date when a drug has several approvals [36].<\/p>\n\n\n\n

            When negotiated prices start<\/strong><\/h3>\n\n\n\n

            Eligibility for selection is not the same as a price change. For the 2028 cycle, CMS published the list on January 27, 2026 [37], and prices take effect January 1, 2028 [36]. Calculation: a small molecule at the cutoff reaches the price date 8 years and 11 months after approval. A biologic at its cutoff reaches it 12 years and 11 months after licensure.<\/p>\n\n\n\n

            The 2025 orphan-drug change<\/strong><\/h3>\n\n\n\n

            The 2025 reconciliation law broadened the orphan drug exclusion. It now covers drugs designated for multiple rare diseases. It also delays the start of the 7- or 11-year clock for orphan drugs that later win a non-orphan approval [36]. KFF reports the change delayed selection of Keytruda and Opdivo beyond 2026. Medicare and beneficiary spending in 2023 was $5.6 billion on Keytruda and $2.0 billion on Opdivo [36]. CBO estimates the provision costs the federal government $8.8 billion over ten years [36].<\/p>\n\n\n\n

            The third negotiation cycle<\/strong><\/h3>\n\n\n\n
            Cycle<\/th>Drugs<\/th>Price effective<\/th>Source<\/th><\/tr><\/thead>
            Initial price applicability year 2026<\/td>10 Part D drugs, including Eliquis, Xarelto, Januvia, Jardiance, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and Fiasp\/NovoLog<\/td>January 1, 2026<\/td>[36]<\/td><\/tr>
            Initial price applicability year 2027<\/td>15 Part D drugs, including Ozempic and Wegovy<\/td>January 1, 2027<\/td>[36]<\/td><\/tr>
            Initial price applicability year 2028<\/td>15 Part B and D drugs: Trulicity, Biktarvy, Orencia, Cosentyx, Erleada, Kisqali, Entyvio, Verzenio, Botox, Lenvima, Xolair, Rexulti, Xeljanz, Anoro Ellipta, Cimzia; Tradjenta selected for renegotiation<\/td>January 1, 2028<\/td>[36][38]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

            The 2028 cycle is the first to include Part B drugs [37]. Four drugs have primarily Part B volume: Botox, Cimzia, Orencia, and Entyvio [39]. The 15 drugs accounted for about $27 billion in Medicare spending, roughly 6% of Part B and Part D spending [37]. CMS announced on March 13, 2026 that all 15 manufacturers chose to participate [40]. CMS must announce negotiated prices by November 30, 2026 [36]. As of September 27, 2026, those prices are not yet published.<\/p>\n\n\n\n

            Cumulative reach<\/strong><\/h4>\n\n\n\n

            The 40 products selected to date accounted for 36% of Medicare Part B and Part D drug spending in 2024, or $125 billion of $350 billion, before rebates [36].<\/p>\n\n\n\n

            Generic or biosimilar marketing ends negotiation<\/strong><\/h4>\n\n\n\n

            If CMS determines that a generic or biosimilar is approved and marketed in good faith, the drug is no longer eligible for negotiation, or an ongoing negotiation is suspended [36]. Authorized generics do not count for this purpose [36].<\/p>\n\n\n\n

            Outside the US: SPCs and the EU Pharma Package<\/strong><\/h2>\n\n\n\n

            EU supplementary protection certificates<\/strong><\/h3>\n\n\n\n

            An SPC can extend a patent for a maximum of 5 years. A further 6-month extension is available when the product has a completed Paediatric Investigation Plan [41]. Regulation (EU) 2019\/933 lets EU-based companies make generic or biosimilar versions during the SPC term for export, or for stockpiling in the last 6 months of the SPC ahead of EU entry [41].<\/p>\n\n\n\n

            Unitary SPC proposal<\/strong><\/h4>\n\n\n\n

            On April 27, 2023, the Commission proposed an SPC reform with a centralised procedure run by EUIPO and a unitary SPC for unitary patents [41].<\/p>\n\n\n\n

            EU regulatory protection reform<\/strong><\/h3>\n\n\n\n

            The current EU system gives 8 years of data protection and 2 years of market protection, with a possible one-year extension for a new indication [43]. The Council and Parliament reached a provisional agreement on the pharma package on December 11, 2025 [42]. The text sets a new baseline of 8 years of data protection plus 1 year of market protection. A law-firm update dated September 24, 2026 says formal adoption was still expected [44].<\/p>\n\n\n\n

            The 2026 to 2030 Patent Cliff: What the Duration Math Means for Revenue<\/strong><\/h2>\n\n\n\n

            Scale of exposure<\/strong><\/h3>\n\n\n\n

            Drug Discovery News reports that the US market alone is projected to lose more than $230 billion in revenue between 2025 and 2030, with Keytruda expected to lose patent protection in 2028 [45]. DrugPatentWatch’s guide cites a wider global range of $200 billion to $400 billion of branded revenue [20]. The ranges differ because each estimate uses its own inclusion rules and dates.<\/p>\n\n\n\n

            What to model<\/strong><\/h3>\n\n\n\n

            Interpretation: a defensible loss-of-exclusivity date is the latest of these dates, adjusted for the events that can pull it earlier:<\/p>\n\n\n\n

              \n
            • The key patent’s expiration, including PTA and any PTE [1][5][6]<\/li>\n\n\n\n
            • Regulatory exclusivity end dates, including the 6-month pediatric add-on [7]<\/li>\n\n\n\n
            • Settlement entry dates, which can precede patent expiry [19]<\/li>\n\n\n\n
            • Skinny-label and Orange Book risk after Hikma and the FTC actions [29][35]<\/li>\n\n\n\n
            • The Medicare negotiation date for selected drugs [36]<\/li>\n<\/ul>\n\n\n\n

              How to Calculate a Drug’s Patent Expiration Date<\/strong><\/h2>\n\n\n\n

              Step-by-step method<\/strong><\/h3>\n\n\n\n
                \n
              1. Identify the key patent in the Orange Book (small molecules) or the Purple Book and litigation record (biologics) [1][22].<\/li>\n\n\n\n
              2. Start with 20 years from the earliest US filing date [1].<\/li>\n\n\n\n
              3. Add PTA days shown on the issued patent [6].<\/li>\n\n\n\n
              4. Add PTE if granted, and check it against the 5-year and 14-year limits [5].<\/li>\n\n\n\n
              5. Add 6 months if pediatric exclusivity attached [7].<\/li>\n\n\n\n
              6. Check NCE, NCI, orphan, and other exclusivity end dates [1].<\/li>\n\n\n\n
              7. Check litigation, 30-month stays, and settlements [25].<\/li>\n\n\n\n
              8. Check Medicare negotiation eligibility [36].<\/li>\n<\/ol>\n\n\n\n

                Common errors<\/strong><\/h4>\n\n\n\n

                Reading only the base expiration date misses PTE. Ignoring the second Orange Book line misses the pediatric add-on [1]. Treating patent expiry as the entry date misses settlements. Humira’s entry came about six years after its compound patent expired [3][4].<\/p>\n\n\n\n

                Where the data lives<\/strong><\/h3>\n\n\n\n

                Primary records include FDA’s Orange Book, the Purple Book, Federal Register PTE notices, and court dockets. Patents and exclusivities that expire are removed from the Orange Book, so a current listing understates history [1]. Commercial databases such as DrugPatentWatch bring patent, litigation, and exclusivity records into one search. Check any date against the FDA, USPTO, or court record before relying on it.<\/p>\n\n\n\n

                Methodology and Limitations<\/strong><\/h2>\n\n\n\n

                Data analyzed: seven FDA regulatory review period notices published in the Federal Register between 2015 and 2026, found by keyword search of the Federal Register. Inclusion criteria: notices that state testing-phase and total review days. Exclusion criteria: notices without both figures. The sample is not random, and it does not represent all extended patents. No duplicate records appeared.<\/p>\n\n\n\n

                Calculation method: formula ceiling = approval phase + (testing phase \/ 2), in days. Years = days \/ 365.25. The 5-year cap = 1,826.25 days. For ALIQOPA, the approval phase equals the total minus the testing phase. The ceiling ignores the patent issue date, due diligence reductions, and the 14-year cap, all of which can lower the granted extension [5]. Actual extensions come from USPTO determinations, not from these calculations.<\/p>\n\n\n\n

                Other calculations: Humira dates assume the compound patent expired at the end of December 2016 [3]. The IRA price-date interval counts from the 2028 cutoff dates [36]. The Farxiga NCE-1 example counts from FDA’s stated approval date [7]. Market exclusivity studies use different cohorts and definitions, and Rome et al. include only four biologics [2]. Law and guidance changes quickly. This guide reflects information found through September 27, 2026 and is not legal advice.<\/p>\n\n\n\n

                Key Takeaways<\/strong><\/h2>\n\n\n\n
                  \n
                1. A US drug patent runs 20 years from the earliest US filing date, before any adjustment or extension [1].<\/li>\n\n\n\n
                2. PTE is capped at 5 years and at 14 years of post-approval patent life. A patent with 14 or more years left after approval gets none [5].<\/li>\n\n\n\n
                3. In seven recent FDA determinations, the half-weighted testing phase supplied 64.9% to 92.2% of the formula ceiling (calculation).<\/li>\n\n\n\n
                4. Observed small-molecule market exclusivity clusters between about 11.5 and 14.4 years [2][16][17].<\/li>\n\n\n\n
                5. Humira held 20 years of US exclusivity, entered about six years after its compound patent expired, and reached entry through settlements [3][4][19].<\/li>\n\n\n\n
                6. The Supreme Court reversed the Federal Circuit in Hikma v. Amarin on June 4, 2026, by a 9 to 0 vote [29].<\/li>\n\n\n\n
                7. Teva asked FDA on December 10, 2025 to remove more than 200 Orange Book listings [35].<\/li>\n\n\n\n
                8. For the 2028 Medicare cycle, small molecules approved by February 1, 2019 and biologics licensed by February 1, 2015 were eligible [36].<\/li>\n<\/ol>\n\n\n\n

                  FAQ<\/strong><\/h2>\n\n\n\n

                  Can a drug patent be renewed?<\/strong><\/h3>\n\n\n\n

                  No. The term can be adjusted for USPTO delay or extended for FDA review time. FDA lists “the patent has not previously been extended” as a condition of PTE, so a patent receives one extension [5][6].<\/p>\n\n\n\n

                  What is the maximum patent term extension?<\/strong><\/h3>\n\n\n\n

                  Five years. Total patent life after approval, including the extension, cannot exceed 14 years [5].<\/p>\n\n\n\n

                  Do generics launch the day a patent expires?<\/strong><\/h3>\n\n\n\n

                  Not always. Humira’s compound patent expired in December 2016, and US biosimilar competition began on January 31, 2023 [3][4]. Settlements set the entry dates [19].<\/p>\n\n\n\n

                  Does pediatric exclusivity extend the patent?<\/strong><\/h3>\n\n\n\n

                  No. It adds 6 months to listed patents and exclusivities, but FDA states it is not an extension of the patent [7].<\/p>\n\n\n\n

                  What is the NCE-1 date?<\/strong><\/h3>\n\n\n\n

                  It is the date 4 years after NDA approval. From that date, an applicant can submit an ANDA or 505(b)(2) application with a Paragraph IV certification if patents are listed [7].<\/p>\n\n\n\n

                  Do biologics qualify for patent term extension?<\/strong><\/h3>\n\n\n\n

                  Yes. FDA’s notices for VYLOY, ENFLONSIA, AMTAGVI, and ENCELTO concern human biological products [11][12][13][14]. FDA’s FAQ defines a human drug product to include a human biologic product [5].<\/p>\n\n\n\n

                  How long is biosimilar exclusivity for a reference biologic?<\/strong><\/h3>\n\n\n\n

                  Twelve years from first approval of the reference product [15]. For Keytruda, approved in September 2014, DrugPatentWatch puts that date at September 2026 [20].<\/p>\n\n\n\n

                  Can a generic launch with a skinny label after Hikma v. Amarin?<\/strong><\/h3>\n\n\n\n

                  The Supreme Court held that a skinny label plus routine marketing statements did not state an inducement claim at the pleading stage [29][30]. Inducement claims remain possible where a brand pleads active encouragement [31].<\/p>\n\n\n\n

                  When does Medicare negotiation start for a new drug?<\/strong><\/h3>\n\n\n\n

                  A small molecule becomes eligible for selection 7 years after approval, and a biologic 11 years after licensure [36]. For the 2028 cycle, the list came out January 27, 2026 [37] and prices start January 1, 2028 [36].<\/p>\n\n\n\n

                  How long does an EU SPC last?<\/strong><\/h3>\n\n\n\n

                  Up to 5 years, plus 6 months for products with a completed Paediatric Investigation Plan [41]. EU data and market protection is changing to 8 plus 1 years under the pharma package, pending formal adoption [44].<\/p>\n\n\n\n

                  References<\/strong><\/h2>\n\n\n\n
                    \n
                  1. U.S. Food and Drug Administration. (2020, February 5). Frequently asked questions on patents and exclusivity<\/em>. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/frequently-asked-questions-patents-and-exclusivity<\/li>\n\n\n\n
                  2. Rome, B. N., Lee, C. C., & Kesselheim, A. S. (2021). Market exclusivity length for drugs with new generic or biosimilar competition, 2012-2018. Clinical Pharmacology & Therapeutics, 109<\/em>, 367-371. https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.1983<\/li>\n\n\n\n
                  3. AbbVie Inc. (2016). Form 424B3 prospectus supplement<\/em>. U.S. Securities and Exchange Commission. https:\/\/www.sec.gov\/Archives\/edgar\/data\/0001551152\/000104746916016654\/a2230267z424b3.htm<\/li>\n\n\n\n
                  4. AbbVie Inc. (2024). Form 10-K for fiscal year 2023<\/em>. U.S. Securities and Exchange Commission. https:\/\/www.sec.gov\/Archives\/edgar\/data\/1551152\/000155115224000011\/abbv-20231231.htm<\/li>\n\n\n\n
                  5. U.S. Food and Drug Administration. (2025, August 15). Small business assistance: Frequently asked questions on the patent term restoration program<\/em>. https:\/\/www.fda.gov\/drugs\/cder-small-business-industry-assistance-sbia\/small-business-assistance-frequently-asked-questions-patent-term-restoration-program<\/li>\n\n\n\n
                  6. Mintz. (2017, June). Calculating patent term adjustment, part 1<\/em>. https:\/\/www.mintz.com\/insights-center\/viewpoints\/2231\/2017-06-calculating-patent-term-adjustment-part-1<\/li>\n\n\n\n
                  7. U.S. Food and Drug Administration, Office of Generic Drugs. (n.d.). Exclusivity: Which one is for me?<\/em> [Presentation]. https:\/\/www.fda.gov\/media\/135234\/download<\/li>\n\n\n\n
                  8. Food and Drug Administration. (2015, December 10). Determination of regulatory review period for purposes of patent extension; ELIQUIS. Federal Register<\/em>. https:\/\/www.federalregister.gov\/documents\/2015\/12\/10\/2015-31096\/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eliquis<\/li>\n\n\n\n
                  9. Food and Drug Administration. (2023, February 14). Determination of regulatory review period for purposes of patent extension; ALIQOPA. Federal Register<\/em>. https:\/\/www.federalregister.gov\/documents\/2023\/02\/14\/2023-03070\/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aliqopa<\/li>\n\n\n\n
                  10. Food and Drug Administration. (2026, January 27). Determination of regulatory review period for purposes of patent extension; EXBLIFEP. Federal Register<\/em>. https:\/\/www.federalregister.gov\/documents\/2026\/01\/27\/2026-01587\/determination-of-regulatory-review-period-for-purposes-of-patent-extension-exblifep<\/li>\n\n\n\n
                  11. Food and Drug Administration. (2026, April 3). Determination of regulatory review period for purposes of patent extension; VYLOY. Federal Register<\/em>. https:\/\/www.federalregister.gov\/documents\/2026\/04\/03\/2026-06478\/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vyloy<\/li>\n\n\n\n
                  12. Food and Drug Administration. (2026, April 3). Determination of regulatory review period for purposes of patent extension; ENFLONSIA. Federal Register<\/em>. https:\/\/www.federalregister.gov\/documents\/2026\/04\/03\/2026-06479\/determination-of-regulatory-review-period-for-purposes-of-patent-extension-enflonsia<\/li>\n\n\n\n
                  13. Food and Drug Administration. (2026, February 13). Determination of regulatory review period for purposes of patent extension; AMTAGVI. Federal Register<\/em>. https:\/\/www.federalregister.gov\/documents\/2026\/02\/13\/2026-02974\/determination-of-regulatory-review-period-for-purposes-of-patent-extension-amtagvi<\/li>\n\n\n\n
                  14. Food and Drug Administration. (2026, April 3). Determination of regulatory review period for purposes of patent extension; ENCELTO. Federal Register<\/em>. https:\/\/www.federalregister.gov\/documents\/2026\/04\/03\/2026-06477\/determination-of-regulatory-review-period-for-purposes-of-patent-extension-encelto<\/li>\n\n\n\n
                  15. I-MAK. (2024, May). Biologics, biosimilars, and patents<\/em>. https:\/\/www.i-mak.org\/wp-content\/uploads\/2024\/05\/Biologics-Biosimilars-Guide_IMAK.pdf<\/li>\n\n\n\n
                  16. Grabowski, H., Kyle, M., Mortimer, R., Long, G., & Kirson, N. (2011). Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act. Health Affairs, 30<\/em>(11), 2157-2166. https:\/\/www.healthaffairs.org\/doi\/abs\/10.1377\/hlthaff.2010.0270<\/li>\n\n\n\n
                  17. Grabowski, H., et al. (2021). Continuing trends in U.S. brand-name and generic drug competition. Journal of Medical Economics<\/em>. https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2021.1952795<\/li>\n\n\n\n
                  18. The Commonwealth Fund. (2017, September 13). Market exclusivity and U.S. prescription drugs<\/em> [Summary of Kesselheim, Sinha, & Avorn, JAMA Internal Medicine]. https:\/\/www.commonwealthfund.org\/publications\/journal-article\/2017\/sep\/determinants-market-exclusivity-prescription-drugs-united<\/li>\n\n\n\n
                  19. Knox, R., & Curfman, G. (2022, October 11). The Humira patent thicket, the Noerr-Pennington doctrine, and antitrust’s patent problem<\/em>. SSRN. https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=4215822<\/li>\n\n\n\n
                  20. DrugPatentWatch. (2026, March 22). Drug patent expiration: The complete strategic guide to loss of exclusivity, lifecycle management, and the $400 billion cliff<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/the-impact-of-drug-patent-expiration-financial-implications-lifecycle-strategies-and-market-transformations\/<\/li>\n\n\n\n
                  21. Fenwick & West LLP. (n.d.). Litigation alert: No exception to statutory requirement that a biosimilar applicant provide notice of intent to market its product<\/em>. https:\/\/www.fenwick.com\/insights\/publications\/litigation-alert-no-exception-to-statutory-requirement-that-a-biosimilar-applicant-provide-notice-of-intent-to-market-its-product<\/li>\n\n\n\n
                  22. Congressional Research Service. (2025, June 12). Pharmaceutical patent disputes: Biosimilar entry under the Biologics Price Competition and Innovation Act (BPCIA)<\/em> (IF13029). https:\/\/www.everycrsreport.com\/files\/2025-06-12_IF13029_af9f98f4ac0f4fd539038ed9e7abf0280218035f.html<\/li>\n\n\n\n
                  23. Jones Day. (2025, December 3). FDA’s biosimilar playbook: Merging biosimilarity with interchangeability<\/em>. https:\/\/www.jonesday.com\/en\/insights\/2025\/12\/fda-biosimilar-playbook-merging-biosimilarity-with-interchangeability<\/li>\n\n\n\n
                  24. U.S. Food and Drug Administration. (2026, March 9). Biosimilars guidances<\/em>. https:\/\/www.fda.gov\/vaccines-blood-biologics\/general-biologics-guidances\/biosimilars-guidances<\/li>\n\n\n\n
                  25. Federal Trade Commission. (2024, December 20). FTC statement on appellate court decision ordering delisting of Teva inhaler patents<\/em>. https:\/\/www.ftc.gov\/news-events\/news\/press-releases\/2024\/12\/ftc-statement-appellate-court-decision-ordering-delisting-teva-inhaler-patents<\/li>\n\n\n\n
                  26. Cooley LLP. (2021, August 17). GSK v. Teva: Federal Circuit opinion after rehearing confirms induced infringement liability despite skinny label<\/em>. https:\/\/www.cooley.com\/news\/insight\/2021\/2021-08-17-gsk-v-teva-federal-circuit-opinion-rehearing-induced-infringement-liability-skinny-label<\/li>\n\n\n\n
                  27. Ropes & Gray LLP. (2026, June 24). Supreme Court slims down the induced infringement cause of action for skinny labels<\/em>. https:\/\/www.ropesgray.com\/en\/insights\/alerts\/2026\/06\/supreme-court-slims-down-the-induced-infringement-cause-of-action-for-skinny-labels<\/li>\n\n\n\n
                  28. Duane Morris LLP. (2026, January 20). U.S. Supreme Court grants certiorari in Hikma v. Amarin, placing “skinny label” inducement in focus<\/em>. https:\/\/www.duanemorris.com\/alerts\/us_supreme_court_grants_certiorari_hikma_amarin_placing_skinny_label_inducement_focus_0126.html<\/li>\n\n\n\n
                  29. Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.<\/em>, No. 24-889 (U.S. June 4, 2026). Legal Information Institute, Cornell Law School. https:\/\/www.law.cornell.edu\/supremecourt\/text\/24-889<\/li>\n\n\n\n
                  30. WilmerHale. (2026, June 10). Supreme Court clarifies pleading standard for induced infringement in Hikma v. Amarin<\/em>. https:\/\/www.wilmerhale.com\/en\/insights\/client-alerts\/20260610-supreme-court-clarifies-pleading-standard-for-induced-infringement-in-hikma-v-amarin<\/li>\n\n\n\n
                  31. Greenberg Traurig LLP. (2026, June 5). The skinny on the Supreme Court’s decision in patent infringement case Hikma v. Amarin<\/em>. https:\/\/www.gtlaw.com\/en\/insights\/2026\/6\/the-skinny-on-the-supreme-courts-decision-in-patent-infringement-case-hikma-v-amarin<\/li>\n\n\n\n
                  32. Federal Trade Commission. (2025, May 21). FTC renews challenge of more than 200 improper patent listings<\/em>. https:\/\/www.ftc.gov\/news-events\/news\/press-releases\/2025\/05\/ftc-renews-challenge-more-200-improper-patent-listings<\/li>\n\n\n\n
                  33. O’Neill Institute for National and Global Health Law. (2025, November 6). Recent developments in Orange Book litigation: How patent disputes shape prescription drug affordability<\/em>. https:\/\/oneill.law.georgetown.edu\/recent-developments-in-orange-book-litigation-how-patent-disputes-shape-prescription-drug-affordability\/<\/li>\n\n\n\n
                  34. DrugPatentWatch. (2026, May 20). Orange Book delisting wave: What the FTC crackdown means for your pipeline<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/orange-book-delisting-wave-what-the-ftc-crackdown-means-for-your-pipeline\/<\/li>\n\n\n\n
                  35. Federal Trade Commission. (2025, December 10). Teva removes over 200 improper patent listings under pressure from FTC<\/em>. https:\/\/www.ftc.gov\/news-events\/news\/press-releases\/2025\/12\/teva-removes-over-200-improper-patent-listings-under-pressure-ftc<\/li>\n\n\n\n
                  36. KFF. (2026, March 11). Key facts about Medicare drug price negotiation<\/em>. https:\/\/www.kff.org\/medicare\/key-facts-about-medicare-drug-price-negotiation\/<\/li>\n\n\n\n
                  37. Centers for Medicare & Medicaid Services. (2026, January 27). CMS announces selection of drugs for third cycle of Medicare Drug Price Negotiation Program, including first-ever Part B drugs<\/em>. https:\/\/www.cms.gov\/newsroom\/press-releases\/cms-announces-selection-drugs-third-cycle-medicare-drug-price-negotiation-program-including-first<\/li>\n\n\n\n
                  38. Medicare Rights Center. (2026, February 5). Medicare drug price negotiations: Selected drugs for 2028<\/em>. https:\/\/www.medicarerights.org\/medicare-watch\/2026\/02\/05\/medicare-drug-price-negotiations-selected-drugs-for-2028<\/li>\n\n\n\n
                  39. Avalere Health. (2026, July 28). CMS announces the third round of Medicare drug price negotiation<\/em>. https:\/\/advisory.avalerehealth.com\/insights\/cms-announces-the-third-round-of-medicare-drug-price-negotiation<\/li>\n\n\n\n
                  40. Centers for Medicare & Medicaid Services. (n.d.). Selected drugs and negotiated prices<\/em>. https:\/\/www.cms.gov\/priorities\/medicare-prescription-drug-affordability\/overview\/medicare-drug-price-negotiation-program\/selected-drugs-negotiated-prices<\/li>\n\n\n\n
                  41. European Commission. (n.d.). Supplementary protection certificates for pharmaceutical and plant protection products<\/em>. https:\/\/single-market-economy.ec.europa.eu\/industry\/strategy\/intellectual-property\/patent-protection-eu\/supplementary-protection-certificates-pharmaceutical-and-plant-protection-products_en<\/li>\n\n\n\n
                  42. Council of the European Union. (2025, December 11; updated 2026, March 6). ‘Pharma package’: Council and Parliament reach a deal on new rules for a fairer and more competitive EU pharmaceutical sector<\/em>. https:\/\/www.consilium.europa.eu\/en\/press\/press-releases\/2025\/12\/11\/pharma-package-council-and-parliament-reach-a-deal-on-new-rules-for-a-fairer-and-more-competitive-eu-pharmaceutical-sector\/<\/li>\n\n\n\n
                  43. Herbert Smith Freehills Kramer. (2026, April). The EU Pharma Package is finally here: The settled position on key areas<\/em>. https:\/\/www.hsfkramer.com\/notes\/ip\/2026-04\/the-eu-pharma-package-finally-here-what-it-changes-and-what-it-means<\/li>\n\n\n\n
                  44. BioSlice Blog. (2026, September 24). Final text of the reform to the EU regulatory framework for medicinal products published<\/em>. https:\/\/www.biosliceblog.com\/2026\/09\/final-text-of-the-reform-to-the-eu-regulatory-framework-for-medicinal-products-published\/<\/li>\n\n\n\n
                  45. Drug Discovery News. (2026, February 24). Blockbuster drugs face a massive patent cliff in 2026<\/em>. https:\/\/www.drugdiscoverynews.com\/blockbuster-drugs-face-a-massive-patent-cliff-in-2026-17019<\/li>\n<\/ol>\n\n\n\n

                    <\/p>\n","protected":false},"excerpt":{"rendered":"

                    A US patent lasts 20 years from filing [1]. A study of 264 small-molecule drugs that faced new generic competition […]<\/p>\n","protected":false},"author":1,"featured_media":39723,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10,14],"tags":[],"class_list":["post-3324","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights","category-tips-tricks-case-studies"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/3324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=3324"}],"version-history":[{"count":0,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/3324\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/39723"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=3324"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=3324"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=3324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}